.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,391,335

« Back to Dashboard

Details for Patent: 6,391,335

Title: Effervescent drug delivery system for oral administration
Abstract:The pharmaceutical compositions of the present invention comprise orally administerable dosage forms that use effervescence as a penetration enhancer for drugs known, or suspected, of having poor bioavailability. Effervescence can occur in the stomach, once the tablet or other dosage form is ingested. In addition to effervescence in the stomach, or as alternative technique, by the use of appropriate coatings and other techniques, the effervescence can occur in other parts of the gastrointestinal tract, including, but not limited to, the esophagus, duodenum, and colon. The site of effervescence and drug release is chosen to correspond with the segment of the gastrointestinal tract displaying maximal absorption of the formulated drug, or to gain some other therapeutic advantage.
Inventor(s): Pather; S. Indiran (Plymouth, MN), Robinson; Joseph R. (Madison, WI), Eichman; Jonathan D. (Ann Arbor, MI), Khankari; Rajendra K. (Maple Grove, MN), Hontz; John (Plymouth, MN), Gupte; Sangeeta V. (Maple Grove, MN)
Assignee: Cima Labs Inc. (Minneapolis, MN)
Filing Date:Jul 10, 2000
Application Number:09/613,270
Claims:1. A dosage form for delivery of a therapeutically effective amount of a drug to a target area in the gastrointestinal tract of a mammal; comprising:

(a) a therapeutically effective amount of a drug;

(b) at least one effervescent penetration enhancer; wherein said at least one effervescent penetration enhancer is present in an amount sufficient to increase the penetration of said drug across said target area of said gastrointestinal tract to permit delivery of a therapeutically effective amount of said drug; and

(c) an enteric coating maintained over said drug and said at least one effervescent penetration enhancer; wherein said enteric coating prevents the release of said drug and said at least one effervescent penetration enhancer until a time at which said dosage form reaches said target area in said gastrointestinal tract.

2. The dosage form of claim 1, further comprising at least one noneffervescent penetration enhancer.

3. The dosage form of claim 1, further comprising at least one disintegration agent, wherein said disintegration agent causes the rapid dispersion of said drug to said target area of said gastrointestinal tract.

4. The dosage form of claim 1, wherein said enteric coating comprises a material that reacts with an enzyme present in said target area of the gastrointestinal tract to release said drug and said effervescent penetration enhancer.

5. The dosage form of claim 1, wherein said dosage form is a tablet.

6. The dosage from of claim 5 wherein said tablet contains a biconcave zone central to two outer zones; wherein said drug and said effervescent penetration enhancer are located in said biconcave zone.

7. The dosage form of claim 1, wherein said two outer zones contain a bioadhesive.

8. The dosage form of claim 1, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple; said effervescent couple comprising an acid or equivalent thereof and a base or equivalent thereof.

9. The dosage form of claim 8 wherein said base is sodium bicarbonate.

10. The dosage form of claim 1 wherein said drug is a drug that displays poor bioavailability in said gastrointestinal tract.

11. The dosage form of claim 1, wherein said effervescent penetration enhancer comprises a pharmaceutically acceptable effervescent couple comprising an acid and a base, wherein said acid is selected from the group consisting of citric, tartaric, amalic, fumeric, adipic, and succinic acids, and said base is selected from the group consisting of sodium bicarbonate, sodium carbonate, potassium bicarbonate, potassium carbonate and magnesium carbonate.

12. The dosage form of claim 2, further comprising a noneffervescent disintegration agent.

13. The dosage form of claim 2, wherein said protective coating comprises a material that reacts with an enzyme present in said area of the gastrointestinal tract to release said drug, said effervescent penetration enhancer and said noneffervescent penetration enhancer.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

How are People Using DrugPatentWatch?

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc